Javaheripour, Nooshin
Li, Meng
Chand, Tara
Krug, Axel http://orcid.org/0000-0002-0564-2497
Kircher, Tilo
Dannlowski, Udo
Nenadić, Igor
Hamilton, J. Paul http://orcid.org/0000-0001-7982-4659
Sacchet, Matthew D.
Gotlib, Ian H. http://orcid.org/0000-0002-3622-3199
Walter, Henrik http://orcid.org/0000-0002-9403-6121
Frodl, Thomas http://orcid.org/0000-0002-8113-6959
Grimm, Simone
Harrison, Ben J.
Wolf, Christian Robert
Olbrich, Sebastian
van Wingen, Guido http://orcid.org/0000-0003-3076-5891
Pezawas, Lukas http://orcid.org/0000-0002-1329-6352
Parker, Gordon
Hyett, Matthew P.
Sämann, Philipp G.
Hahn, Tim http://orcid.org/0000-0001-6541-3795
Steinsträter, Olaf
Jansen, Andreas
Yuksel, Dilara
Kämpe, Robin
Davey, Christopher G. http://orcid.org/0000-0003-1431-3852
Meyer, Bernhard
Bartova, Lucie http://orcid.org/0000-0002-1769-8025
Croy, Ilona
Walter, Martin
Wagner, Gerd http://orcid.org/0000-0003-2296-0259
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB779-A06)
Article History
Received: 3 August 2021
Revised: 31 August 2021
Accepted: 13 September 2021
First Online: 7 October 2021
Competing interests
: SG has served as consultant to and received research support from Boehringer Ingelheim. MW performed studies with institutional research support from HEEL and from Janssen Pharmaceutical Research for an IIT on ketamine in patients with MDD, which is unrelated to this investigation. MW has not received any personal financial compensation from third parties. All other co-authors declared no conflict of interests.